Kyntra Bio, Inc. (KYNB) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KYNB SEC filings page.
Kyntra Bio, Inc. (KYNB) reported $6.4M in revenue for fiscal year 2025, down 78.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Kyntra’s latest statements describe a development-stage operation whose reported profit is disconnected from cash while obligations exceed assets.
Earnings quality changed sharply across periods: FY2024 showed a net loss, while FY2025 reported net income despite still-negative operating cash flow. That combination indicates the latest accounting profit was driven by items that did not translate into operating cash, rather than by the underlying development activity itself.
Development spending dominates the operating model: research and development consumed
The balance sheet has contrasting signals: a current ratio of 3.4x suggests current assets exceed near-term liabilities, but total liabilities equal
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Kyntra Bio, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Kyntra Bio, Inc.'s reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 13/100.
Kyntra Bio, Inc.'s revenue declined 78.3% year-over-year, from $29.6M to $6.4M. This contraction results in a growth score of 1/100.
With a current ratio of 3.39, Kyntra Bio, Inc. holds $3.39 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 83/100.
Kyntra Bio, Inc.'s operations used $4.8M of cash, and capex of $38K added to the outflow, for a free cash flow shortfall of $4.8M. This results in a cash flow score of 2/100.
Kyntra Bio, Inc. scores -20.41, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $1.7B against total assets of $119.6M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Kyntra Bio, Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
For every $1 of reported earnings, Kyntra Bio, Inc. used $0.03 of operating cash (-$4.8M OCF vs $183.5M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Kyntra Bio, Inc. reported an operating loss of $45.9M against $8.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Kyntra Bio, Inc.'s EBITDA was -$17.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Kyntra Bio, Inc. reported $12.0M in net income in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Kyntra Bio, Inc. earned $2.96 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Cash & Balance Sheet
Kyntra Bio, Inc. recorded an outflow of $4.0M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 131.5% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Kyntra Bio, Inc. held $50.6M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
Kyntra Bio, Inc. invested $6.8M in research and development in Q2 2026. This represents an increase of 16.3% from the same quarter a year earlier. Against the prior quarter it is down 9.8%.
Kyntra Bio, Inc. reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
KYNB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $3.7M+36.5% | $1.3M-59.3% | $1.1M+774.8% | $1.3M+35.1% | $2.7M-89.2% | $3.1M | $123K-99.7% |
| Cost of Revenue | $2K-97.6% | $4.1M+1529.4% | $277Kn/m | -$58Kn/m | $85K-39.3% | $252K-98.8% | -$5.8M | -$75K-101.8% |
| Gross Profit | -$1.5M-216.9% | -$368K-114.8% | N/A | N/A | $1.3M+47.2% | $2.5M-38.1% | N/A | N/A |
| R&D Expenses | $6.8M+16.3% | $7.6M-17.5% | $7.3M+5.8% | $1.2M-93.9% | $5.9M-81.9% | $9.2M-74.9% | $6.9M | $20.0M-67.4% |
| SG&A Expenses | $9.3M+31.3% | $5.9M-27.7% | $7.3M-13.1% | $5.3M-43.4% | $7.1M-52.7% | $8.1M-51.5% | $8.3M | $9.4M-63.4% |
| Operating Income | -$17.6Mn/m | -$13.8Mn/m | -$13.5Mn/m | -$5.4Mn/m | -$12.1Mn/m | -$14.9Mn/m | -$7.1M | -$47.7Mn/m |
| EBITDA | -$17.6Mn/m | -$13.8Mn/m | -$13.5Mn/m | -$5.2Mn/m | -$11.8Mn/m | -$14.6Mn/m | -$6.8M | -$47.0Mn/m |
| Interest Expense | $2.4M+17.9% | $2.4M+7.5% | $2.4M+8.7% | $2.1M+0.7% | $2.0M+7.5% | $2.3M+7.9% | $2.2M | $2.1M-58.8% |
| Income Tax | -$1Kn/m | $0-100.0% | $0-100.0% | $0-100.0% | -$92Kn/m | $2K-71.4% | $2K | $3K-96.4% |
| Net Income | $12.0Mn/m | -$15.2M-427.6% | -$14.2M-179.1% | $200.6Mn/m | -$7.6Mn/m | $4.6Mn/m | $18.0M | -$17.1Mn/m |
| EPS (Basic) | $2.96n/m | -$3.76 | -$3.53 | $49.61n/m | -$1.88 | $1.15 | $0.18n/m | -$4.25 |
| EPS (Diluted) | $2.96n/m | -$3.76 | -$3.53 | $49.61n/m | -$1.88 | $1.15 | $0.18n/m | -$4.25 |
| Diluted Shares (Avg) | 4M+0.1% | 4M | N/A | 4M+0.6% | 4M | 4M | N/A | 4M |
KYNB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $101.1M-43.2% | $109.6M-33.6% | $119.6M-44.3% | $137.0M-48.2% | $178.1M-39.3% | $165.2M-54.8% | $214.5M-49.3% | $264.4M-42.6% |
| Current Assets | $96.8M-40.4% | $101.4M-31.8% | $99.1M-49.6% | $133.4M-45.4% | $162.3M-22.5% | $148.5M-46.6% | $196.5M-40.7% | $244.5M-32.8% |
| Cash & Equivalents | $50.6M+116.7% | $37.0M+10.1% | $47.9M-5.2% | $118.0M-9.9% | $23.4M-83.4% | $33.6M-68.2% | $50.5M-38.1% | $131.0M+8.3% |
| Short-Term Investments | $40.7Mn/m | $50.2Mn/m | $41.1Mn/m | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0-100.0% |
| Inventory | $3.4M-12.4% | $3.4M+7.3% | $3.7M+18.6% | $3.9M-83.9% | $3.9M-84.8% | $3.2M-88.5% | $3.2M-81.6% | $23.9M-41.2% |
| Accounts Receivable | $347K+155.1% | $5.0M+3328.6% | $216K-55.1% | $121K-99.6% | $136K-97.9% | $147K-99.6% | $481K-90.6% | $29.0M-8.4% |
| Long-Term Investments | $4.0Mn/m | $8.0Mn/m | $20.2Mn/m | $3.0Mn/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $131.2M-67.3% | $153.4M-59.8% | $149.6M-62.4% | $154.0M-67.0% | $401.1M-17.1% | $382.1M-30.8% | $398.2M-32.0% | $466.1M-19.0% |
| Current Liabilities | $36.0M-76.9% | $28.1M-61.7% | $29.2M-78.1% | $36.0M-81.1% | $155.9M+4.9% | $73.4M-62.7% | $133.3M-38.8% | $190.5M-9.0% |
| Non-Current Liabilities | $95.2M-61.2% | $125.3M-59.4% | $120.4M-54.5% | $118.1M-57.2% | $245.2M-26.8% | $308.7M-13.1% | $264.9M-28.0% | $275.6M-24.7% |
| Long-Term Debt | N/A | N/A | N/A | $75.0M | N/A | N/A | N/A | N/A |
| Total Equity | -$30.1Mn/m | -$43.8Mn/m | -$30.0Mn/m | -$17.0Mn/m | -$223.0Mn/m | -$216.9Mn/m | -$225.6Mn/m | -$243.7Mn/m |
| Retained Earnings | -$1.7Bn/m | -$1.7Bn/m | -$1.7Bn/m | -$1.7Bn/m | -$1.9Bn/m | -$1.9Bn/m | -$1.9Bn/m | -$1.9Bn/m |
Not reported in any period shown, so not listed: Goodwill.
KYNB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.0M-131.5% | -$13.9M-610.7% | -$18.3Mn/m | -$1.8Mn/m | $12.7Mn/m | $2.7Mn/m | -$30.5Mn/m | -$8.4Mn/m |
| Depreciation & Amortization | $6K-97.3% | $7K-97.9% | $8K-97.7% | $192K-74.0% | $221K-71.7% | $327K-60.1% | $352K-81.2% | $739K-68.9% |
| Stock-Based Compensation | N/A | $1.2M-59.6% | N/A | N/A | N/A | $2.9M-67.5% | N/A | N/A |
| Capital Expenditures | $0-100.0% | $0-100.0% | $0-100.0% | $9K-89.0% | $13K-7.1% | $16K-44.8% | $141K-43.8% | $82K-88.0% |
| Free Cash Flow | -$4.0M-131.5% | -$13.9M-613.8% | -$18.3Mn/m | -$1.9Mn/m | $12.7Mn/m | $2.7Mn/m | -$30.6Mn/m | -$8.5Mn/m |
| Investing Cash Flow | $17.7Mn/m | $3.0Mn/m | -$51.7M-3101.3% | $87.2M+11444.4% | -$13K-100.0% | -$16K-100.0% | $1.7M-83.2% | $755K-98.6% |
| Financing Cash Flow | -$5Kn/m | -$7Kn/m | -$14K-380.0% | -$85.9Mn/m | -$9K-128.1% | -$88Kn/m | $5Kn/m | -$127Kn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
KYNB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | -9.8%-100.6pp | N/A | N/A | 93.7%+7.7pp | 90.8%+75.0pp | N/A | N/A |
| Operating Margin | N/A | -369.7% | -1058.1% | -502.9% | -894.1% | -544.7% | -227.5% | -38774.0% |
| Net Margin | N/A | -406.6% | -1113.5% | 18646.5% | -564.0% | 169.4% | 573.4% | -13889.4% |
| Return on Assets | 11.8%+16.1pp | -13.9%-16.7pp | -11.9%-20.3pp | 146.4%+152.9pp | -4.3%+1.0pp | 2.8%+11.8pp | 8.4% | -6.5%+7.4pp |
| Current Ratio | 2.69+1.6x | 3.61+1.6x | 3.39+1.9x | 3.71+2.4x | 1.04-0.4x | 2.02+0.6x | 1.470.0x | 1.28-0.5x |
| Asset Turnover | -0.010.0x | 0.030.0x | 0.010.0x | 0.010.0x | 0.010.0x | 0.02-0.1x | 0.01 | 0.00-0.1x |
| FCF Margin | N/A | -371.5% | -1435.2% | -172.5% | 939.8% | 98.7% | -976.0% | -6876.4% |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, Liabilities-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$30.0M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Where Kyntra Bio, Inc. Ranks
Frequently Asked Questions
What is Kyntra Bio, Inc.'s annual revenue?
Kyntra Bio, Inc. (KYNB) reported $6.4M in total revenue for fiscal year 2025. This represents a -78.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Kyntra Bio, Inc.'s revenue growing?
Kyntra Bio, Inc. (KYNB) revenue declined by 78.3% year-over-year, from $29.6M to $6.4M in fiscal year 2025.
Is Kyntra Bio, Inc. profitable?
Yes, Kyntra Bio, Inc. (KYNB) reported a net income of $183.5M in fiscal year 2025.
What is Kyntra Bio, Inc.'s EBITDA?
Kyntra Bio, Inc. (KYNB) had EBITDA of -$45.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Kyntra Bio, Inc.'s gross margin?
Kyntra Bio, Inc. (KYNB) had a gross margin of 91.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Kyntra Bio, Inc.'s free cash flow?
Kyntra Bio, Inc. (KYNB) recorded an outflow of $4.8M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Kyntra Bio, Inc.'s operating cash flow?
Kyntra Bio, Inc. (KYNB) recorded an outflow of $4.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Kyntra Bio, Inc.'s total assets?
Kyntra Bio, Inc. (KYNB) had $119.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Kyntra Bio, Inc.'s capital expenditures?
Kyntra Bio, Inc. (KYNB) invested $38K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Kyntra Bio, Inc. spend on research and development?
Kyntra Bio, Inc. (KYNB) invested $23.5M in research and development during fiscal year 2025.
What is Kyntra Bio, Inc.'s current ratio?
Kyntra Bio, Inc. (KYNB) had a current ratio of 3.39 as of fiscal year 2025, which is generally considered healthy.
What is Kyntra Bio, Inc.'s return on assets (ROA)?
Kyntra Bio, Inc. (KYNB) had a return on assets of 153.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Kyntra Bio, Inc.'s P/E ratio?
Kyntra Bio, Inc. (KYNB) trades at 0.1x earnings, its market capitalization divided by $183.2M net income, trailing 12 months to June 30, 2026. The market capitalization is $18.5M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Kyntra Bio, Inc.'s price-to-sales ratio?
Kyntra Bio, Inc. (KYNB) trades at 2.9x sales, its market capitalization divided by $6.4M revenue, FY2025. The market capitalization is $18.5M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is Kyntra Bio, Inc.'s debt-to-equity ratio negative or not reported?
Kyntra Bio, Inc. (KYNB) has negative shareholder equity of -$30.0M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Kyntra Bio, Inc.'s Altman Z-Score?
Kyntra Bio, Inc. (KYNB) has an Altman Z-Score of -20.41, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Kyntra Bio, Inc.'s Piotroski F-Score?
Kyntra Bio, Inc. (KYNB) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Kyntra Bio, Inc.'s earnings high quality?
For every $1 of reported earnings, Kyntra Bio, Inc. (KYNB) used $0.03 of operating cash (-$4.8M OCF vs $183.5M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Kyntra Bio, Inc. cover its interest payments?
Kyntra Bio, Inc. (KYNB) reported an operating loss of $45.9M against $8.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Kyntra Bio, Inc.?
Kyntra Bio, Inc. (KYNB) scores 24 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.